|
1
|
Gravalos C and Jimeno A: HER2 in gastric
cancer: a new prognostic factor and a novel therapeutic target. Ann
Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hofmann M, Stoss O, Shi D, et al:
Assessment of a HER2 scoring system for gastric cancer: results
from a validation study. Histopathology. 52:797–805. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pala EE, Bayol U, Ozguzer A and Akman O:
HER2 status in gastric cancer: a comparison of two novel in situ
hybridization methods (IQ FISH and dual color SISH) and two
immunohistochemistry methods (A0485 and HercepTest™). Pathol Res
Pract. 209:548–554. 2013.PubMed/NCBI
|
|
4
|
Watson S, Validire P, Cervera P, et al:
Combined HER2 analysis of biopsies and surgical specimens to
optimize detection of trastuzumab-eligible patients in eso-gastric
adenocarcinoma: a GERCOR study. Ann Oncol. 24:3035–3039. 2013.
View Article : Google Scholar
|
|
5
|
Bang YJ: Advances in the management of
HER2-positive advanced gastric and gastroesophageal junction
cancer. J Clin Gastroenterol. 46:637–648. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: ToGA Trial Investigators: Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Lancet. 376:687–697. 2010. View Article : Google Scholar
|
|
7
|
Daum O, Skálová A, Rozkos T and Laco J:
Predictive diagnosis of HER2 in gastric adenocarcinoma. Cesk Patol.
47:160–163. 2011.(In Czech).
|
|
8
|
Ooi A, Kobayashi M, Mai M and Nakanishi I:
Amplification of c-erbB-2 in gastric cancer: detection in
formalin-fixed, paraffin-embedded tissue by fluorescence in situ
hybridization. Lab Invest. 78:345–351. 1998.PubMed/NCBI
|
|
9
|
Man YG, Moinfar F, Bratthauer GL, et al:
An improved method for DNA extraction from paraffin sections.
Pathol Res Pract. 197:635–642. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jacquemier J, Spyratos F, Esterni B, et
al: SISH/CISH or qPCR as alternative techniques to FISH for
determination of HER2 amplification status on breast tumors core
needle biopsies: a multicenter experience based on 840 cases. BMC
Cancer. 13:3512013. View Article : Google Scholar
|
|
11
|
Fock KM: Review article: the epidemiology
and prevention of gastric cancer. Aliment Pharmacol Ther.
40:250–260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sehdev A and Catenacci DV:
Gastroesophageal cancer: focus on epidemiology, classification, and
staging. Discov Med. 16:103–111. 2013.PubMed/NCBI
|
|
13
|
Brien TP, Depowski PL, Sheehan CE, Ross JS
and McKenna BJ: Prognostic factors in gastric cancer. Mod Pathol.
11:870–877. 1998.PubMed/NCBI
|
|
14
|
Fox SB, Kumarasinghe MP, Armes JE, et al:
Gastric HER2 Testing Study (GaTHER): an evaluation of
gastric/gastroesophageal junction cancer testing accuracy in
Australia. Am J Surg Pathol. 36:577–582. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hirschmann A, Lamb TA, Marchal G, Padilla
M and Diebold J: Simultaneous analysis of HER2 gene and protein on
a single slide facilitates HER2 testing of breast and gastric
carcinomas. Am J Clin Pathol. 138:837–844. 2012. View Article : Google Scholar
|
|
16
|
Cho EY, Srivastava A, Park K, et al:
Comparison of four immunohistochemical tests and FISH for measuring
HER2 expression in gastric carcinomas. Pathology. 44:216–220. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kiyose S, Igarashi H, Nagura K, et al:
Chromogenic in situ hybridization (CISH) to detect HER2 gene
amplification in breast and gastric cancer: comparison with
immunohistochemistry (IHC) and fluorescence in situ
hybridization (FISH). Pathol Int. 62:728–734. 2012.
|
|
18
|
Lee S, de Boer WB, Fermoyle S, Platten M
and Kumarasinghe MP: Human epidermal growth factor receptor 2
testing in gastric carcinoma: issues related to heterogeneity in
biopsies and resections. Histopathology. 59:832–840. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takehana T, Kunitomo K, Kono K, et al:
Status of c-erbB-2 in gastric adenocarcinoma: a comparative study
of immunohistochemistry, fluorescence in situ hybridization
and enzyme-linked immuno-sorbent assay. Int J Cancer. 98:833–837.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yano T, Doi T, Ohtsu A, et al: Comparison
of HER2 gene amplification assessed by fluorescence in situ
hybridization and HER2 protein expression assessed by
immunohistochemistry in gastric cancer. Oncol Rep. 15:65–71.
2006.PubMed/NCBI
|
|
21
|
Grin A, Brezden-Masley C, Bauer S and
Streutker CJ: HER2 in situ hybridization in gastric and
gastroesophageal adenocarcinoma: comparison of automated dual ISH
to FISH. Appl Immunohistochem Mol Morphol. 21:561–566. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yan B, Yau EX, Choo SN, et al: Dual-colour
HER2/chromosome 17 chromogenic in situ hybridisation assay enables
accurate assessment of HER2 genomic status in gastric cancer and
has potential utility in HER2 testing of biopsy samples. J Clin
Pathol. 64:880–883. 2011. View Article : Google Scholar
|
|
23
|
Marx AH, Tharun L, Muth J, et al: HER-2
amplification is highly homogenous in gastric cancer. Hum Pathol.
40:769–777. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
García-García E, Gómez-Martin C, Angulo B,
et al: Hybridization for human epidermal growth factor receptor 2
testing in gastric carcinoma: a comparison of fluorescence in-situ
hybridization with a novel fully automated dual-colour silver
in-situ hybridization method. Histopathology. 59:8–17.
2011.PubMed/NCBI
|
|
25
|
Kim MA, Jung EJ, Lee HS, et al: Evaluation
of HER-2 gene status in gastric carcinoma using
immunohistochemistry, fluorescence in situ hybridization, and
real-time quantitative polymerase chain reaction. Hum pathol.
38:1386–1393. 2007.
|
|
26
|
Tvrdík D, Staněk L, Skálová H, Dundr P,
Velenská Z and Povysil C: Comparison of the IHC, FISH, SISH and
qPCR methods for the molecular diagnosis of breast cancer. Mol Med
Rep. 6:439–443. 2012.PubMed/NCBI
|
